Dr. Kevin Kim did his medical school at the University of Illinois College of Medicine and his internship at the VA Westside Medical Center. He did his residency in internal medicine at the Mayo School of Graduate Medical Education and his fellowship in medical oncology at the University of Texas Health Science Center. Dr. Kim is a board-certified oncologist and practices at the California Pacific Medical Center and University of Texas MD Anderson Cancer Center. He has been practicing for about 20 years and has also contributed to over 80 research papers.
University of Illinois College of Medicine
VA Westside Medical Center
Mayo School of Graduate Medical Education
University of Texas Health Science Center
American Board of Internal Medicine - Oncology
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong, D. S.,Kurzrock, R.,Wheler, J. J.,Naing, A.,Falchook, G. S.,Fu, S.,Kim, K. B.,Davies, M. A.,Nguyen, L. M.,George, G. C.,Xu, L.,Shumaker, R.,Ren, M.,Mink, J.,Bedel...; Clin. Cancer Res.. 2015 Jul 15.See more >>
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Hong, D. S.,Kurzrock, R.,Falchook, G. S.,Andresen, C.,Kwak, J.,Ren, M.,Xu, L.,George, G. C.,Kim, K. B.,Nguyen, L. M.,O'Brien, J. P.,Nemunaitis, J.; Oncotarget. 2015 Oct 28.See more >>
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy, A. E.,Boland, G. M.,Milton, D. R.,Roszik, J.,Frankian, S.,Malke, J.,Haydu, L.,Prieto, V. G.,Tetzlaff, M.,Ivan, D.,Wang, W. L.,Torres-Cabala, C.,Curry, J.,Roy-Ch...; J. Invest. Dermatol.. 2014 Aug 26.See more >>